A novel gene on human chromosome 2p24 is differentially expressed between androgen-dependent and androgen-independent prostate cancer cells
Introduction
Prostate cancer is the second leading cause of male cancer-related deaths and the most commonly diagnosed cancer in elderly men in the Western world [1]. Prostate cancer is initially an androgen-dependent disease and can be treated effectively by inhibiting endogenous androgen production or action. However, it has been reported that in an animal model, almost all prostate tumours will progress, which results in growth of androgen-independent cells and subsequent development of hormone-refractory prostate disease. The mechanism of prostate cancer progression from an androgen-dependent to an androgen-independent state is not fully understood [2]. Genetic alterations (loss and gain) most likely play a role during prostate cancer progression. It has been reported that major genetic alterations occur during androgen-dependent prostate cancer growth, and minor genetic alterations occur during androgen-independent prostate cancer growth 3, 4. Identification of genetic factors that are differentially expressed between androgen-dependent and androgen-independent prostate cancer may be important to extend our current knowledge of the molecular mechanism(s) underlying the development of hormone-refractory prostate cancer.
Applying differential display reverse transcriptase-polymerase chain reaction (RT-PCR) analysis to androgen-dependent and androgen-independent prostate cancer cells, we have identified and cloned several cDNA transcripts 5, 6, 7. Here, we report on the identification of a novel gene, designated GC109. GC109 is localised on the human chromosome 2p24 locus and was found to be expressed more highly in androgen-dependent compared with androgen-independent prostate cancer cell lines.
Section snippets
Human cancer cell lines
The lymph node carcinoma of the prostate-fast growing colony (LNCaP-FGC) and lymph node carcinoma of the prostate-lymph node original (LNCaP-LNO) cell lines [8] were gifts from Dr J.S. Horoszewicz (Buffalo, NY, USA) and were propagated as described in 5, 9.
The human cancer cell lines PC3 and DU145 (androgen-independent prostate carcinomas), ZR-75-1 (oestrogen-dependent breast carcinoma), T47D and MCF7 (oestrogen-responsive breast carcinomas), MDA-MB-231 and SKBR-3 (oestrogen-independent breast
GC109 is differentially expressed between LNCaP-FGC and LNCaP-LNO cells
Two genetically related LNCaP cell lines were used to isolate genes involved in androgen-independent prostate cancer development. The LNCaP-FGC cell line is androgen-dependent and has an optimal growth rate at 10−10 M R1881 (synthetic androgen), whereas higher concentrations did not stimulate growth at all. Both 10−7 M 1.25 (OH)2D3 (vitamin D3) or a combination of 10−8 M R1881 plus 10−7 M 1.25 (OH)2D3 did not stimulate growth (data not shown). The LNCaP-LNO cell line is androgen-independent and
Discussion
Using differential display RT-PCR analysis and a controlled cell culture system, GC109 was identified (Fig. 1). GC109 mRNA is higher expressed in androgen-dependent LNCaP-FGC compared with androgen-independent LNCaP-LNO prostate cancer cells. In normal human tissues, GC109 mRNA expression was not limited to the prostate, but was also observed in various other human tissues (Fig. 2). In fetal tissues, expression was in general lower compared with their normal human counterparts, except for fetal
Acknowledgments
This work was sponsored by the Dutch Cancer Society (KWF/NKB) (grant no. EUR 95-1031).
References (22)
- et al.
Genetic alterations in hormone-refractory recurrent prostate carcinomas
Am. J. Pathol.
(1998) - et al.
The human prostatic cancer cell line LNCaP and its derived sublinesan in vitro model for the study of androgen sensitivity
J. Steroid. Biochem. Mol. Biol.
(1991) - et al.
Basic local alignment search tool
J. Mol. Biol.
(1990) - et al.
Does this have a familiar RING?
Trends Biochem. Sci.
(1996) - et al.
Nuclear targeting sequences—a consensus?
Trends Biochem. Sci.
(1991) - et al.
Cancer statistics, 2001
CA Cancer J. Clin.
(2001) - et al.
Molecular and cellular changes associated with the acquisition of metastatic ability by prostatic cancer cells
Prostate
(1994) - et al.
Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping
Cancer Res.
(1996) - et al.
Differentially expressed genes in androgen-dependent and-independent prostate carcinomas
Cancer Res.
(1997) - et al.
Identification of a gene on human chromosome 8q11, that is differentially expressed during prostate-cancer progression
Int. J. Cancer
(1999)
Characterization of a zinc-finger protein and its association with apoptosis in prostate cancer cells
J. Natl. Cancer Inst.
Cited by (6)
The prostate cancer-up-regulated long noncoding RNA PlncRNA-1 modulates apoptosis and proliferation through reciprocal regulation of androgen receptor
2013, Urologic Oncology: Seminars and Original InvestigationsCitation Excerpt :AR pathway hyperactivation can result from hypersensitivity to androgen, aberrant androgen synthesis, abnormal activation by co-regulator alterations, or alternative pathways, such as growth factors, receptor tyrosine kinases [3–5]. Identification of genes involved in the transition from androgen-dependent to androgen-independent prostate cancer (AIPC) is important to extend our current knowledge of AIPC [6]. Mammalian genomes transcribe a wide array of RNA molecules.
Id-1 expression in androgen-dependent prostate cancer is negatively regulated by androgen through androgen receptor
2009, Cancer LettersCitation Excerpt :It is therefore necessary to identify mechanisms underlying the emergence of AIPC before a novel therapeutic strategy for AIPC can be developed. Identification of genes involved in the transition from androgen-dependent to androgen-independent prostate cancer is important to extend our current knowledge of AIPC [5]. Id-1 (inhibitors of differentiation and DNA binding-1) is a helix–loop–helix (HLH) protein that belongs to the Id protein family [6].
Differentially expressed genes in the prostate cancer cell line LNCaP after exposure to androgen and anti-androgen
2006, Cancer Genetics and CytogeneticsCitation Excerpt :Eighty percent of these patients show an initial therapeutic response to hormonal manipulation, however most of these patients relapse within three years with an androgen independent carcinoma, which has no effective treatment [2,3]. Identification of differentially expressed genes between androgen dependent and androgen independent prostate cancer may be important to understand the mechanisms underlying the development of hormone refractory prostate cancer [4]. Androgen regulated genes (ARGs) represent potential targets for early diagnosis and treatment of prostate cancer patients [5].
Genetic factors underlying prostate cancer
2003, Expert Reviews in Molecular MedicineLong non-coding RNAs and prostate cancer
2013, Journal of Nanoscience and NanotechnologyActivin a stimulates AKR1C3 expression and growth in human prostate cancer
2012, Endocrinology